Measures of pulmonary function, such as FEV 1 and FEV 1 /FVC ratio, are important predictors of population morbidity and mortality [1] [2] [3] [4] as well as forming the basis for the diagnosis of COPD. It is well established that pulmonary function is partially genetically determined. Twin studies in European and US populations give heritability estimates for FEV 1 as high as 0.77 (refs. 5,6). Longitudinal studies in families suggest that genetic effects are consistent over time 7 . Genetic determinants of pulmonary function seem to operate, at least in part, independent of disease status (such as asthma) and smoking status 8 , suggesting that population-based association studies are a viable way to identify key genetic determinants of lung function.
year, GWAS have reported association between an intergenic locus at chromosome 4q31 and FEV 1 /FVC ratio and COPD, but no large-scale collaborative GWAS have yet been undertaken for lung function 10, 11 .
If common SNPs underlying lung function have modest effects, very large sample sizes will be required to identify them. We therefore established the SpiroMeta consortium to facilitate large-scale metaanalysis of GWAS of lung function. Here we report a meta-analysis of GWAS in the SpiroMeta consortium, comprising 20,288 individuals of European ancestry, that tested association between cross-sectional lung function measures and ~2.5 million genotyped or imputed SNPs (stage 1). We followed up SNPs drawn from the most significantly associated loci in up to 32,184 individuals by direct genotyping (stage 2a) and using in silico summary association data relating to a further 22,092 individuals (stage 2b). These studies confirm the previous reported association at 4q31 and show that five previously unreported loci are robustly associated with lung function.
RESULTS

Genome-wide association with lung function (stage 1)
We included 14 studies of individuals of European ancestry, with sample sizes totaling 20,288 ( Table 1 ). All individuals had measures of FEV 1 and FVC and smoking status recorded. FEV 1 and (separately) FEV 1 /FVC measures were adjusted for age, age 2 , sex, height and ancestry principal components within each study. Genome-wide genotyping was Fig. 1a,b) .
We observed independent regions of association at 17 loci with P < 1 × 10 −5 for FEV 1 and 23 for FEV 1 /FVC (Figs. 1a,b and 2), including three regions (4q24 in GSTCD, 4q31 near HHIP and 15q23 in THSD4) that reached P < 5 × 10 −8 in the stage 1 GWAS data alone, corresponding to a threshold of P < 0.05 after adjusting for 1 million independent tests 12 . SNP rs12504628, which was associated with both FEV 1 /FVC (P = 6.48 × 10 −13 ; Fig. 2c and Table 2 ) and FEV 1 (P = 1.50 × 10 −10 ; Table 3 ), lies in an For rs12504628, the plot shows only the association of FEV 1 /FVC; this SNP was associated (P < 5 × 10 −8 ) with both FEV 1 and FEV 1 /FVC. Fine-scale recombination rate is plotted in blue 39 . Combined P value from stages 1 and 2a only; SNP rs3995090 had low imputation quality in the CHARGE Consortium data and so was not included in stage 2b. Shown are the top SNPs or SNPs for each independent locus associated (P < 5 × 10 −7 ) with FEV 1 or FEV 1 /FVC in a joint analysis of up to 74,564 individuals of European ancestry from the SpiroMeta GWAS (stage 1), follow-up genotyping (stage 2a) and in silico data from the CHARGE Consortium (companion paper in this issue 30 ) and the Health 2000 study (stage 2b). The six genome-wide significant (P < 5 × 10 −8 ) loci are indicated in bold. Results are also shown for rs2395730 (DAAM2), as this locus fell just below genomewide significance after meta-analysis of stage 1 and 2b data (it was not selected for stage 2a genotyped follow-up). For the GWAS (stage 1 and 2b) data, the sample sizes (N) shown are the effective sample sizes. Effective sample size within each study is the product of sample size and imputation quality metric. Total sample size is the sum of the N effective values across all stage 1 and 2b studies, plus the sample size from the directly genotyped (stage 2a) studies; for each SNP, this is lower than 74,564 individuals owing to missing genotypes and imperfect imputation. Joint meta-analysis includes data from stages 1, 2a and 2b. Beta values reflect effect-size estimates on an inverse-normal transformed scale after adjustments for age, age 2 , sex, height and ancestry principal components. SNP rs12504628 showed association with both FEV 1 and FEV 1 /FVC (P < 5 × 10 −8 ); statistics for the strongest association (FEV 1 /FVC) are shown. As this association has been previously published 11 , rs12504628 was not assessed in the follow-up studies, so statistics are not presented for stages 2a and 2b for rs12504628. SNP rs3995090 was genotyped in stage 2a follow-up studies and was available in Health 2000 study data, but owing to low imputation quality for rs3995090 in the CHARGE Consortium data, an alternative SNP in the region, rs6889822, was selected for in silico exchange with the CHARGE Consortium. The estimated proportion of variance explained by each SNP in the joint meta-analysis is shown (r 2 ). ns, nonsynonymous coding SNP.
intergenic region upstream of HHIP and spanning ~300 kb at 4q31 that has been associated with lung function 11 , COPD 11 and height 9 .
Our top SNP rs12504628 was in strong linkage disequilibrium (LD; r 2 = 0.97) with the previously reported SNP associated with lung function, rs13147758 (P = 5.30 × 10 −10 for FEV 1 and P = 1.11 × 10 −12 for FEV 1 /FVC in our data), and with SNPs associated previously with height (rs6854783, r 2 = 0.55; rs2055059, r 2 = 0.48), suggesting a role in skeletal growth and development. The hedgehog gene family, of which HHIP is a member, encodes signaling molecules involved in regulating lung morphogenesis, suggesting other mechanisms underlying these associations 13 . This intergenic region also contains multiple ESTs in human fetal lung (UCSC Browser).
Follow-up analyses (stage 2)
To Fig. 2) . A further locus, 6p21 in DAAM2, which was not selected for further genotyping follow-up in stage 2a, fell just below the threshold for genome-wide significance for association with FEV 1 /FVC after meta-analysis across stages 1 and 2b (rs2395730, P = 7.98 × 10 −8 ; Supplementary Table 3 and Table 2 ).
The strongest association of FEV 1 was at 4q24 in GSTCD (rs10516526, P = 2.18 × 10 −23 ; Table 2 and Fig. 2b) . Relatively little is known about GSTCD, but the presence of the C-terminal α-helical domain common to the glutathione S-transferase (GST) family of enzymes suggests this protein is involved in cellular detoxification by catalyzing conjugation of glutathione to products of oxidative stress 14 . GST enzymes also show glutathione peroxidase activity regulating the synthesis of prostaglandins and leukotrienes 14 . To explore the potential function of GSTCD, we conducted a protein homology search and identified homology with chloride intracellular channels 1, 3, 4, 5 and 6, suggesting a role for GSTCD beyond the GST enzyme family. Genes in the region also include INTS12 and NPNT. INTS12 associates with RNA polymerase II and mediates 3′-end processing of small nuclear RNA 15 . 
A r t i c l e s
The second locus associated with FEV 1 was at 2q35, localized to the TNS1 gene (nonsynonymous coding SNP rs2571445, P = 1.11 × 10 −12 ; Table 2 and Fig. 2a) . The protein this encodes, tensin-1, is an actinbinding protein that contains Src homology 2 domains, suggesting a role in linking cytoskeletal changes with signal transduction 16 . Tensin-1 may be functionally involved in cell migration 17 .
Multiple genes potentially underlie the third locus associated with FEV 1 at 5q33. The most strongly associated SNPs in this region, rs3995090 and rs6889822 (P = 4.29 × 10 −9 and P = 8.17 × 10 −9 ; Table 2 and Fig. 2d) , are located in an intron in HTR4 and are part of a cluster of associated SNPs also spanning a SPINK5-like gene, SPINK7, SPINK9 and FBXO38. HTR4, which encodes 5-hydroxytryptamine receptor-4, is expressed in neurons in the respiratory pre-Bötzinger complex. Activation of this G protein-coupled receptor protects spontaneous respiratory activity 18 . Notably, selective antagonism of HTR4 in human bronchial strips in vitro attenuates the facilitation of electric field-stimulated cholinergic contraction by 5-hydroxytryptamine, suggesting a role for HTR4 in mediating airway caliber 19 . HTR4 expression has recently been confirmed in airway epithelial type II cells, where receptor stimulation seems to regulate cytokine responses 20 . The SPINK family of serine protease inhibitors may have a role in antimicrobial protection of mucous epithelia 21 . F-box protein-38 (encoded by FBXO38) is a member of a family of proteins that are believed to mediate protein-protein interactions and protein degradation 22 .
The strongest association with FEV 1 /FVC was at 6p21, a generich region of the major histocompatibility complex (MHC). The extended LD in this region of the MHC prevented accurate localization of the association signal. However, we observed the peak of association for a nonsynonymous coding SNP in AGER (rs2070600, P = 3.07 × 10 −15 ; Table 2 and Fig. 2e ), which is a plausible candidate for causal association. AGER, also known as RAGE, is a multiligand receptor of the immunoglobulin superfamily 23 . AGER is highly expressed in the lung, in particular alveolar epithelial cells 24 , with a potential role in epithelium-extracellular matrix interactions. Reduced AGER expression has been identified in individuals with idiopathic pulmonary fibrosis 25 , and Ager −/− mice develop agerelated pulmonary fibrosis 26 . Another candidate in this region is the nearby gene NOTCH4, a member of the family of transmembrane receptors involved in cell fate decisions 27 . Notch4 is expressed in endothelial cells of the adult mouse lung, where it is believed to regulate angiogenesis 28 .
The second identified association with FEV 1 /FVC was at 15q23, encompassing the THSD4 gene (rs12899618, P = 7.24 × 10 −15 ; Table 2 and Fig. 2f) . THSD4 shows homology with members of the thrombospondin family of extracellular calcium-binding proteins that modulate cellular attachment, proliferation and migration and have been implicated in wound healing, inflammation and angiogenesis 29 .
For each of the loci we reported, the estimated effect sizes were broadly consistent across the GWAS (Fig. 3) .
Association of variants with FVC
We tested the top SNP at each of the loci showing genome-wide significant association (P < 5 × 10 −8 ) with FEV 1 or FEV 1 /FVC for association with the other of the two traits, and with FVC in the stage 1 studies ( Table 3 ). In addition to being associated with FEV 1 , rs10516526 in GSTCD was associated with FVC (P = 2.53 × 10 −7 ) but showed no discernible effect on FEV 1 /FVC. Each SNP included in table showed genome-wide significant association (P < 5 × 10 −8 ) with either FEV 1 or FEV 1 /FVC in data from stages 1, 2a and 2b. Beta values shown reflect effect-size estimates on an inverse-normal transformed scale in the stage 1 data. Effective sample size was calculated within each study as the product of sample size and imputation quality metric and were summed across studies to calculate total effective sample size (N). Estimates from analyses unadjusted for smoking status and adjusted for ever-smoking versus never-smoking status are shown.
A r t i c l e s
Effect of smoking on SNP associations Adjustment for ever-smoking status in the stage 1 data ( Table 3) did not show materially different effect-size estimates for the associations with the sentinel SNPs in TNS1, GSTCD, HTR4, AGER, THSD4 or HHIP. Similarly, adjustments for a quantitative measure of lifetime smoking exposure (pack-years) did not show substantially different effect-size estimates for the identified SNP associations (data not shown). We also tested the associations of the top SNPs in TNS1, GSTCD, HTR4, AGER and THSD4 separately in ever-smokers and never-smokers (Supplementary Table 4) ; all P values were >0.05 for tests of interaction between smoking status and these SNPs on lung function.
Gene expression
We determined the mRNA expression profiles of GSTCD, HHIP, THSD4, TNS1, HTR4, AGER and NOTCH4 in human lung tissue and a series of primary cells. We detected all transcripts in lung tissue (Supplementary Fig. 2a ) and bronchial epithelial cells ( Supplementary Fig. 2b) ; six transcripts (excluding NOTCH4) were present in human airway smooth muscle cells. We also detected GSTCD, TNS1, HTR4, AGER and NOTCH4 transcripts in peripheral blood mononuclear cells (Supplementary Fig. 2b ). For AGER, we noted the presence of two PCR products suggesting an unreported splice variant; we confirmed the presence of the splice variant by sequencing.
DISCUSSION
Our study reports a meta-analysis of GWAS results from 20,288 participants and follow-up analyses in 54,276 participants, identifying five novel genome-wide significant loci for pulmonary function. The regions identified were 4q24 (GSTCD), 2q35 (TNS1) and 5q33 (HTR4) for FEV 1 , and 6p21 (AGER) and 15q23 (THSD4) for FEV 1 /FVC. In addition, we identified a region suggestive of association with FEV 1 /FVC at 6p21 in DAAM2. The companion manuscript from the CHARGE Consortium, which reports a GWAS of lung function in 20,890 participants, also identifies genome-wide significant associations at GSTCD, HTR4 and AGER 30 . Both SpiroMeta and CHARGE confirmed the previously reported association between FEV 1 and FEV 1 /FVC and the 4q31 locus upstream of HHIP 11 . Our findings have several important implications. First, the loci identified were observed in the whole population studied and were not specific to smokers. The presence of genetic determinants of lung function that do not depend on prior smoking exposure has been suggested by previous studies of heritability 8 . This does not rule out a possible subset of genetic determinants with effects on lung function that are partially or wholly dependent on smoking exposure.
We have also attempted to address the issue of genetic factors that influence smoking behavior. We did not observe any association with the CHRNA3-CHRNA5-CHRNB4 locus previously reported to be associated with cigarette smoke exposure, lung cancer, peripheral arterial disease 31 and COPD 10 (rs1051730, P = 0.23 for FEV 1 and 0.56 
A r t i c l e s
for FEV 1 /FVC). The associations we show in GSTCD, TNS1, HTR4, THSD4 and AGER do not seem to be attenuated by adjustment for qualitative or quantitative adjustments for smoking exposure. None of these loci have been implicated in published GWAS of smoking quantity, although a recent report suggested a role for TSHD4 variants in smoking cessation 32 .
SNPs showing association with height could also show association with lung function measures because of incomplete adjustment for height, or because of SNP effects on skeletal growth with consequences for both height and lung function. The 4q31 locus near HHIP has shown convincing association with height 33 . An association was recently reported between height and rs185819 at 6p21 (ref. 34) . Although this association signal was broad, reflecting the extended LD across this region of the MHC, rs185819 was in weak LD (r 2 = 0.069) with rs2070600 (the sentinel SNP we reported for FEV 1 /FVC in AGER). These findings leave open the possibility of shared genetic determinants of growth of pulmonary function and height, but they do not suggest that our findings are primarily accounted for by inadequate adjustment for height.
The level of FEV 1 at a given time point in an individual depends on two potentially independent processes: the maximum lung function obtained during development, and the rate of decline of lung function with age. Lung function reaches a maximum by age 25-35 years 35 . The populations studied in SpiroMeta cover a wide range of ages except the very elderly; as expected, FEV 1 and FVC values were much lower in children. At least for the loci we identify, there was little evidence for age-specific effects, suggesting that the genetic risk factors identified operate across the age ranges; these findings again are in keeping with those of previous epidemiological studies 7 . Our analyses were based on cross-sectional measures of lung function; additional studies in cohorts with longitudinal data will be needed to identify determinants of the gradients of development and decline in lung function with age.
The magnitude of the estimated effect on untransformed FEV 1 of rs10516526 in GSTCD was 52 ml per copy of the G allele (frequency, 0.06). This is equivalent to about 3 years of FEV 1 decline in the nonsmoking population 35 . Allelic effect sizes on FEV 1 of the more common variants (minor allele frequencies ~0.4) were 19-23 ml for rs3995090 in HTR4 and rs2571445 in TNS1. Individually, the five loci we describe account for a small proportion (0.07%-0.14%) of the variance in FEV 1 and in FEV 1 /FVC (Table 2) in the general population.
After exclusion of the locus near HHIP and the five reported regions, meta-analysis test statistics still showed an excess of extreme values compared with expected values under the null, particularly for FEV 1 . Although we cannot rule out the possibility of residual population stratification, this indicates the potential to detect further loci associated with lung function (Supplementary Fig. 1a,b) . We have provided a list of the top 2000 associations for FEV 1 and for FEV 1 /FVC (Supplementary Table 5 ) as a resource to other investigators.
We imputed nongenotyped SNPs using two software implementations 36,37 that share similar underlying population genetic models 38 . This methodology facilitates meta-analysis across different marker sets and improves coverage across the genome, and its utility has been empirically shown in several large GWAS. However, the power to detect associations with rare alleles is limited. The loci we report include two relatively infrequent SNPs, GSTCD (rs10516526, minor allele frequency 0.06) and AGER (rs2070600, minor allele frequency 0.05); these SNPs were directly genotyped in the majority of stage 1 subjects (16,514 and 15,386 individuals, respectively).
The associations we report relate to the general population but were of comparable magnitude after the exclusion of documented cases of asthma or COPD (data not shown). Although pulmonary function is an important predictor of morbidity and mortality per se, it will be important to investigate, in appropriately powered studies, whether the risk alleles in the genes identified in this study act as independent susceptibility markers for COPD or influence the development of airway obstruction in other diseases, such as asthma.
Our expression profiling studies identified expression of all of the candidate genes in relevant tissues. Further work is required to elucidate the mechanisms underlying the novel association signals we describe. In broad terms, however, it is notable that the most probable candidate genes in the regions identified seem to be involved either in developmental pathways important for lung growth or in tissue remodeling pathways that might be expected to alter airway architecture.
In conclusion, the results presented here from the SpiroMeta consortium, together with those reported by the CHARGE Consortium 30 , provide strong evidence for newly identified genetic loci that act as important determinants of pulmonary function.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
